Published in Cancer Weekly, September 30th, 1996
The studies were conducted in the prostate cancer research laboratory of Dr. Cary N. Robertson, M.D., Duke University Medical Center (DUMC) in Durham, North Carolina. The Duke researchers demonstrated in vitro that a single low dose treatment with Demeter's leading anti-cancer Peptidyl MIM (Membrane Interactive Molecule) killed 98 percent of the cell line PC-3, a common prostate cancer model.
The Demeter Peptidyl MIM also was effective against cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.